FDA approval of Zonisade to control partial seizures (convulsions) in the treatment of epilepsy.
Eton Pharmaceuticals, Inc. announced that the FDA has approved Zonisade (zonisamide oral suspension).
Zonisade was included in Eton’s multi-product neurology oral solution partnership with Azurity Pharmaceuticals announced in February of 2021. Under the agreement, Eton is entitled to receive an additional $5 million payment upon the launch of Zonisade, royalty on net sales, and up to $15 million of commercial milestones tied to the combined sales of all three products in the partnership. Azurity Pharmaceuticals will be responsible for the commercialization of Zonisade, and no marketing expenses will be incurred by Eton.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.